Partitioned Survival Analysis | Branch | Sources |
---|---|---|
Overall Survival (OS) | Dab+Tram Placebo | |
Distant Metastasis Free Survival (DMFS) | Dab+Tram Placebo | |
Relapse Free Survival (RFS) | Dab+Tram Placebo | |
Overall Survival, Relapse Free Survival (RFS), and Distant Metastasis Free Survival (DMFS) | Nivolumab | Indirect comparisons using Hauschild (Dab+Tram vs. Placebo) [46], Eggermont (Ipilimumab vs. Placebo) [21] and Ascierto (Nivolumab vs. Ipilimumab) [37]] |
Markov sub-model for disease progression | Sub-model structure based Gerbasi et.al. (2019) [40] | |
Transition RFS - > Death | All branches | General mortality for the German population (starting age 50 years) [41] |
Transition RFS - > Progression | All branches | Assumption RFS- > Locoregional 33%, RFS- > Distant metastases 67% (based on [46], Table 1) |
Transition locoregional progression - > Distant metastases 1st line treatment | All branches | Based on DMFS associated to the respective treatment branch. Hazard ratio increased by a factor of 1.5 (assumption) (similar approach as in [40]). Level of increase is lower compared to [40] |
Transition Locoregional progression - > Death | All branches | Hazard ratio for distant metastases, 2nd Line - > Death (2LOS) in [40], Fig. 2C. Hazard ratio decreased by factor 0.35 (assumption) |
Transition distant metastases 1st line treatment - > 2nd line treatment | All branches | Hazard ratio for Distant metastases, 1st line - > 2nd line. Source: [40], Fig. 2B. |
Transition distant metastases 1st line treatment - > Death | All branches | Hazard ratio for distant metastases, 2nd Line - > Death (2LOS). Source: [40], Fig. 2C |
Transition distant metastases 2nd line treatment - > Death | All branches | Hazard ratio for distant metastases, 2nd Line - > Death (2LOS). Source: [40], Fig. 2C |